Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lava Therapeutics
Biotech
Lava burnt by failure clinical-stage cancer drug in phase 1
Lava Therapeutics has jettisoned its only wholly owned clinical-stage asset after the blood cancer drug “did not reach Lava’s internal benchmarks.”
James Waldron
Dec 10, 2024 9:15am
Seagen pays Lava $50M for preclinical T-cell engager for cancer
Sep 26, 2022 11:00am
Novo, Sanofi VC units lead Lava's $83M series C
Sep 17, 2020 8:25am
J&J taps Lava to develop anti-cancer gamma-delta T-cell engagers
May 15, 2020 8:35am
